Technology area: Biotechnology & Pharmaceuticals
55 pending office actions • 32 art units • 50 examiners • 0 of 55 (0%) have an AI response strategy ready • 68 patents granted in the last 365 days
Takeda Pharmaceutical Company Limited has 58 pending office actions in Biotechnology & Pharmaceuticals. The portfolio spans 53 distinct examiners and 32 distinct art units, reflecting a large and widely distributed prosecution workload. The pending-action figure exceeds the examiner figure, so some examiners handle multiple matters, while the art-unit figure shows concentration across fewer units than examiners.
SITTON, JEHANNE SOUAYA is the busiest examiner, with 2 pending matters. That assignment represents a limited portion of the overall workload, making portfolio-level coordination important. Counsel can use common issue tracking for recurring technical or claim themes, but responses must remain tailored to the separate examiner and art-unit contexts.
Based on the USPTO statutory response window for each pending office action. 16 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 16 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (7%) |
| §103 only | 11 (20%) |
| §112 only | 10 (18%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 11 (20%) |
| Multi-statute (no §101) | 17 (31%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SITTON, JEHANNE SOUAYA | 2 | 53.2% | +47.5% |
| DEKARSKE, MADELINE MCGUIRE | 2 | 20.0% | +50.0% |
| HADDAD, MAHER M | 2 | 50.6% | +53.8% |
| ZOU, NIANXIANG | 2 | 64.0% | +25.0% |
| SIFFORD, JEFFREY MARK | 2 | 55.1% | +32.8% |
| DAVIS, RUTH A | 1 | 60.9% | +31.0% |
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| REILLY, SOPHIA JANE | 1 | 60.0% | +49.4% |
| MARTIN, KEVIN STEPHEN | 1 | 77.4% | +23.3% |
| ARIANI, KADE | 1 | 75.0% | +32.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17769452 | METHOD FOR EVALUATING DRUG TOXICITY | MARTIN, RACHEL E | 127d overdue |
| 17556857 | PURIFICATION OF FVIII FROM PLASMA USING SILICON OXIDE ADSORPTION | ESPINOSA, CLAUDIA EDILMA | 66d overdue |
| 17416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | SIFFORD, JEFFREY MARK | 46d overdue |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | BUTTICE, AUDREY L | 16d |
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | DAVIS, RUTH A | — |
| 18852426 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | REILLY, SOPHIA JANE | — |
| 18850485 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | MARTIN, KEVIN STEPHEN | — |
| 18678709 | MARIBAVIR COMPOSITIONS AND USES THEREOF | HELM, CARALYNNE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17274016 | DENGUE VACCINE UNIT DOSE AND ADMINISTRATION THEREOF | SIFFORD, JEFFREY MARK | 87d overdue |
| 17416810 | NOROVIRUS VACCINE FORMULATIONS AND METHODS | SIFFORD, JEFFREY MARK | 46d overdue |
| 18537204 | RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA | SITTON, JEHANNE SOUAYA | 34d |
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | DAVIS, RUTH A | — |
| 18852426 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | REILLY, SOPHIA JANE | — |
| 18850485 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | MARTIN, KEVIN STEPHEN | — |
| 18829900 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | ARIANI, KADE | — |
| 18550474 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | DEKARSKE, MADELINE MCGUIRE | — |
| Art Unit | Apps |
|---|---|
| 1641 | 5 |
| 1644 | 4 |
| 1671 | 4 |
| 1627 | 3 |
| 1682 | 3 |
| 1647 | 3 |
| 1622 | 3 |
| 1654 | 3 |
| 1651 | 2 |
| 1638 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18952409 | STABILIZED LIQUID AND LYOPHILIZED ADAMTS13 FORMULATIONS | DAVIS, RUTH A | 1699 | §102§112Other | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18908457 | HETEROCYCLIC COMPOUND | RAHMANI, NILOOFAR | 1691 | §112Other | Non-Final OA | — | Pending | Oct 07, 2024 |
| 18852426 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | REILLY, SOPHIA JANE | 1627 | §103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18850485 | SOLID FORMS OF TYK2 INHIBITORS AND METHODS OF USE | MARTIN, KEVIN STEPHEN | 1624 | §103§112 | Non-Final OA | — | Pending | Sep 24, 2024 |
| 18829900 | METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | ARIANI, KADE | 1651 | §103§112DP | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18678709 | MARIBAVIR COMPOSITIONS AND USES THEREOF | HELM, CARALYNNE E | 1615 | §103§112 | Non-Final OA | — | Pending | May 30, 2024 |
| 18710764 | CELL PRODUCTION METHOD | WILSON, MICHAEL C | 1638 | §102§103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18662935 | COMBINATIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF IMMUNE GLOBULIN AND HYALURONIDASE | ORWIG, KEVIN S | 3991 | §102§103§112DPOther | Non-Final OA | — | Pending | May 13, 2024 |
| 18657004 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | KLINKEL, KORTNEY L | 1627 | §101DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18697196 | METHOD FOR MEASURING CELL CONCENTRATION | TAVERNINI, BREANNA MARIE | 1682 | §103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18691573 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | HOLLAND, PAUL J | 1656 | §102§112 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18689723 | INFUSION PUMP | SCHMIDT, EMILY LOUISE | 3783 | §102§112 | Non-Final OA | — | Pending | Mar 06, 2024 |
| 18684541 | SELECTIVE MEASUREMENT OF HUMAN FACTOR VIII | THOMPSON, CURTIS A | 1798 | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18292574 | CAR-EXPRESSING IMMUNE CELLS THAT SPECIFICALLY TARGET MESOTHELIN AND USES THEREOF | METCALF, MATTHEW CURRAN | 1647 | §102§103 | Non-Final OA | — | Pending | Jan 26, 2024 |
| 18544966 | EVALUATION, ASSAYS AND TREATMENT OF PKALMEDIATED DISORDERS | SZPERKA, MICHAEL EDWARD | 1641 | §112Other | Final Rejection | — | Pending | Dec 19, 2023 |
| 18539876 | METHOD FOR PRODUCING NATURAL KILLER CELLS FROM PLURIPOTENT STEM CELLS | BELYAVSKYI, MICHAIL A | 1644 | §103DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18537204 | RNA BIOMARKERS FOR HEREDITARY ANGIOEDEMA | SITTON, JEHANNE SOUAYA | 1682 | §112 | Final Rejection | 34d | Pending | Dec 12, 2023 |
| 18379047 | VIRAL INHIBITORS, THE SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | LAU, JONATHAN S | 1693 | §103Other | Non-Final OA | 9d | Pending | Oct 11, 2023 |
| 18285714 | THERAPEUTIC METHODS USING CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | TAYLOR, LIA ELAN | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Oct 05, 2023 |
| 18553348 | USE OF AN OREXIN 2 RECEPTOR AGONIST FOR POST OPERATION RECOVERY | HOWELL, THEODORE R | 1628 | §103Other | Final Rejection | — | Pending | Sep 29, 2023 |
| 18550474 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | DEKARSKE, MADELINE MCGUIRE | 1622 | §112Other | Final Rejection | — | Pending | Sep 14, 2023 |
| 18550571 | PLASMA KALLIKREIN INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 1627 | §112DP | Non-Final OA | 79d overdue | Pending | Sep 14, 2023 |
| 18550504 | INHIBITORS OF PLASMA KALLIKREIN | DEKARSKE, MADELINE MCGUIRE | 1622 | §102§103§112Other | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18550306 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | FERGUSON, JALISA HOLMES | 1626 | §112DP | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18546384 | CELL THERAPY COMPOSITIONS AND METHODS FOR MODULATING TGF-B SIGNALING | HOWARD, ZACHARY C | 1674 | §102§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18231982 | FORMULATIONS COMPRISING GLUCOCEREBROSIDASE AND ISOFAGOMINE | CURRENS, GRANT CARSON | 1651 | §103Other | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18361790 | METHODS AND COMPOSITIONS FOR CRYOPRESERVATION OF IMMUNE CELLS | HUMPHRIES, NICHOLAS ADAM | 1631 | §103 | Final Rejection | — | Pending | Jul 28, 2023 |
| 18224308 | METHOD AND APPARATUS FOR PROVIDING A PHARMACOKINETIC DRUG DOSING REGIMEN | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §101§103§112DP | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | BUTTICE, AUDREY L | 1647 | §103§112Other | Non-Final OA | 16d | Pending | Jun 13, 2023 |
| 18256565 | COMPOSITIONS OF GUANYLYL CYCLASE C (GCC) ANTIGEN BINDING AGENTS AND METHODS OF USE THEREOF | HADDAD, MAHER M | 1641 | Other | Final Rejection | — | Pending | Jun 08, 2023 |
| 18318218 | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | STOICA, ELLY GERALD | 1647 | §112 | Non-Final OA | — | Pending | May 16, 2023 |
| 18316988 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | COFFA, SERGIO | 1658 | §103DP | Non-Final OA | 55d | Pending | May 12, 2023 |
| 18248604 | DETERMINATION OF CELLULAR KINETICS AND BIODISTRIBUTION FOR CAR-T CELLS | SITTON, JEHANNE SOUAYA | 1682 | §101§103§112 | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18025315 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Non-Final OA | 76d | Pending | Mar 08, 2023 |
| 17916441 | ADAMTS13 VARIANT, COMPOSITIONS, AND USES THEREOF | ROBINSON, HOPE A | 1652 | §112 | Non-Final OA | 72d overdue | Pending | Sep 30, 2022 |
| 17906433 | IMPLANTABLE CELL CHAMBER DEVICE AND USES THEREOF | BECKHARDT, LYNDSEY MARIE | 1613 | §103 | Final Rejection | 16d overdue | Pending | Sep 15, 2022 |
| 17759992 | TREATMENT OF MENORRHAGIA IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE BY ADMINISTRATION OF RECOMBINANT VWF | BARSKY, JARED | 1628 | §103§112 | Non-Final OA | — | Pending | Aug 02, 2022 |
| 17773467 | METHOD FOR PRODUCING T CELLS | ABBOTT, KODYE LEE | 1634 | §112 | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17769452 | METHOD FOR EVALUATING DRUG TOXICITY | MARTIN, RACHEL E | 1657 | §101§103§112 | Non-Final OA | 127d overdue | Pending | Apr 15, 2022 |
| 17622580 | TRANSFECTION METHOD | MEJIAS, SAMANTHA LEE | 1618 | §103DP | Non-Final OA | 15d | Pending | Dec 23, 2021 |
| 17556857 | PURIFICATION OF FVIII FROM PLASMA USING SILICON OXIDE ADSORPTION | ESPINOSA, CLAUDIA EDILMA | 1654 | §102§103§112 | Final Rejection | 66d overdue | Pending | Dec 20, 2021 |
| 17491813 | EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS | PETRASH, HILARY ANN | 1644 | §112 | Final Rejection | 8d | Pending | Oct 01, 2021 |
| 17362191 | METHODS OF PROPHYLACTIC TREATMENT USING RECOMBINANT VWF (rVWF) | AUDET, MAURY A | 1654 | §103 | Non-Final OA | 79d | Pending | Jun 29, 2021 |
| 17416859 | T-CELL RECEPTOR MODIFIED OBJECT | GEORGE, DENNIS CHERIAN | 1644 | §103DP | Final Rejection | — | Pending | Jun 21, 2021 |
| 17326884 | RECOMBINANT VIRAL VECTORS AND NUCLEIC ACIDS FOR PRODUCING THE SAME | JOHNSON, ALLISON MARIE | 1638 | §103 | Final Rejection | — | Pending | May 21, 2021 |
| 17279228 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | D' AMBROSIO, THEA | 1654 | §103§112DP | Final Rejection | — | Pending | Mar 24, 2021 |
| 17263675 | METHOD FOR PRODUCING CD3-POSITIVE CELL | SHUPE, ELIZABETH A | 1643 | §103 | Final Rejection | 19d | Pending | Jan 27, 2021 |
| 16817671 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | KIM, YUNSOO | 1641 | §112Other | Final Rejection | — | Pending | Mar 13, 2020 |
| 16208294 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY AND METHODS OF TREATMENT | HADDAD, MAHER M | 1641 | DP | Non-Final OA | — | Pending | Dec 03, 2018 |
| 14437902 | METHOD FOR PREPARATION OF A HIGH CONCENTRATION LIQUID FORMULATION OF AN ANTIBODY | JUEDES, AMY E | 1644 | §103DP | Final Rejection | — | Pending | Apr 23, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTakeda Pharmaceutical Company Limited has 55 pending office actions as of October 2026, spread across 32 art units and 50 examiners.
Jehanne Souaya Sitton has the most, with 2 of Takeda Pharmaceutical Company Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
